Business
INVO Bioscience Announces Closing of Financing
SARASOTA, Fla., June 29, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla., June 29, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced the second closing of its convertible note and unit purchase option private placement. The Company had previously conducted a first closing on May 15, 2020. The combination of both closings resulted in gross proceeds of $3,093,640 (of which $2,950,000 was received in cash and $143,640 resulted from cancellation of indebtedness).\n\n \n \n \n \n \n \n\n \n\"We appreciate the financial support from our investors as we execute our mission toward increasing patient access and treatment within the infertility marketplace through our revolutionary INVOcell device, an affordable, scalable and effective solution. We continue to push forward with our global commercialization efforts with our major U.S. partner, along with our current partners in Africa, Eurasia, and India; and are pursuing many other key regions and partners in Central and South America, Europe, and Asia Pacific,\" stated Steve Shum, Chief Executive Officer of INVO Bioscience. \nFull details of the transaction can be found in an 8-K filed with the Securities and Exchange Commission at www.SEC.gov. \nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.\nAbout INVO Bioscience\nWe are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our disruptive new technology solution, the INVO Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo de...